Recent scientific investigations are shedding light on how rapid-acting antidepressants and immunotherapies operate in patients with difficult-to-treat depression. Treatment-resistant depression occurs when symptoms persist after multiple antidepressant treatments or talk therapy. While rapid-acting antidepressants such as ketamine and psilocybin can work quickly for some patients, clinicians have historically lacked reliable biomarkers to predict individual responses.
Immune Signals and Novel Pathways in Difficult-to-Treat Depression
Researchers from The University of Texas MD Anderson Cancer Center uncovered that rapid-acting antidepressants alter communication signals between the immune system and the brain. Co-led by assistant professor of Psychiatry Gregory Jones, the study published in UT MD Anderson revealed that these diverse therapies share specific neuroimmune pathways, even while acting on different brain receptors. Ketamine and psychedelics affect the brain in different ways subjectively, but our findings suggest that they eventually end up in some of the same neuroimmune pathways,
Jones said.
Biomarkers and Biological Mechanisms
To evaluate these effects, investigators analyzed multiple rapid-acting antidepressants using laboratory models alongside a previous clinical trial. They observed matching immune-related molecular changes in brain cells and patients’ blood, accompanied by related shifts in brain electrical activity following ketamine administration. Participants who responded to ketamine demonstrated lower IL-15 pathway activity and higher B cell signaling prior to treatment compared to nonresponders. These baseline measures subsequently reversed in patients who achieved a response, pointing to a restored balance between IL-7 and IL-15.
Additional insights regarding molecular mechanisms emerged from Nature, which detailed bulk RNA sequencing assessing time-dependent effects on cortical neurons. Most hallmark signaling pathways were downregulated at six hours and upregulated at 24 hours following drug treatments. Specifically, interferon gamma and alpha responses, IL6-Jak-STAT3, IL2-STAT5, allograft rejection, and complement and coagulation pathways showed upregulation at 24 hours across all evaluated treatments.
Clinical Trials Testing Immunotherapy Targets
Complementing laboratory discoveries, clinical evaluations of targeted immunotherapy have advanced. According to findings published in Sciencedaily on May 20, a pilot study led by the University of Bristol tested whether the rheumatoid arthritis drug tocilizumab could alleviate symptoms in patients with treatment-resistant depression and signs of low-grade inflammation. The trial involved 30 participants recruited via the University of Cambridge and the Cambridgeshire and Peterborough NHS Foundation Trust, with 14 receiving tocilizumab and 16 receiving a saltwater placebo over a four-week period.
Although the small sample size limited statistical evidence of major differences between the two study arms, participants receiving tocilizumab generally exhibited greater improvements in depression severity, anxiety, fatigue, and overall quality of life. Furthermore, researchers reported a 54% depression remission rate among participants taking tocilizumab, compared to 31% in the placebo group.
Golam Khandakar, Professor of Psychiatry and Immunology at the University of Bristol and senior author of the study, noted that the trial marks a milestone in developing targeted options for difficult-to-treat depression. Senior research associate Éimear Foley added that the work advances the goal of tailored care that aligns treatments with an individual patient’s underlying biology.
